Compare KLA Corp. (KLAC) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KLA Corp. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? KLA Corp. trades at $195.57 (market cap $256.72B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: KLA Corp. is far larger — about 4.4× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold KLA Corp. for 60 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| KLAC | TAK | |
|---|---|---|
Market Cap | $256.72B | $58.74B |
Volume | 9,970,753 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $301.71 | $19.05 |
52-Week Low | $98.28 | $13.23 |
Typical Hold Time | 60 Days | 1 Days |
Enterprise Value | $257.97B | $86.65B |
Dividend Yield | 0.47% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KLA Corporation (KLAC) trades at $196.72, showing minimal daily movement with strong fundamental performance. The stock maintains bullish technical signals with support at $193 and resistance at $201. Recent earnings consistently beat expectations, with Q2 2026 EPS of $1.05 exceeding the $1.00 forecast. The company demonstrates robust profitability with 35.57% net income margin and 87.5% ROE, supported by AI-driven semiconductor equipment demand and a $12.57 billion backlog.
Outlook remains positive with analyst consensus target of $223.88 offering 14% upside potential. Key opportunities include AI infrastructure growth and advanced packaging demand, while risks involve competitive pressure from Applied Materials and ASML, along with execution challenges in meeting ambitious $26 billion revenue target by 2030. Institutional ownership trends show continued confidence with recent acquisitions by Envestnet Portfolio Solutions.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
